By continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our Cookie Policy.
We Believe in Partnering
Overview
Together We Can Reach Any Patient Anywhere
Our objective is to ensure that NexoBrid is accessible to burn patients around the world. We are making substantial progress by collaborating and engaging with leaders in various geographic regions, thereby extending our global presence. By working together, we aim to establish NexoBrid as the new benchmark in burn patient care, enhancing their well-being and quality of life.
We are actively expanding the commercialization of NexoBrid through global partnerships. Currently, we operate in over 44 countries and are determined to accelerate our momentum. We firmly believe that success lies in people. Exceptional individuals make exceptional partners. By combining our technology and team with our partners’ professionalism, local marketing expertise, and sales knowledge, we will significantly elevate the standard of care for patients.
Strategic Partnerships
To advance our mission, we actively pursue collaborations and seek strategic partnerships. By joining forces with like-minded organizations and individuals, we can amplify our impact and drive meaningful change. Together, we can work towards our shared goals and make a lasting difference in the communities we serve. If you are interested in partnering with us or would like to explore collaboration opportunities, we welcome your involvement and encourage you to reach out. Together, we can create a brighter future.
We are proud of our strategic collaboration in the U.S with the Advanced Biomedical, Research and Development Authority (BARDA), supporting the development and authorization of NexoBrid in the U.S, as well as procurement of NexoBrid for the U.S national emergency stockpile. We are also delighted to be in partnership with the U.S. Department of Defense to develop NexoBrid as a non-surgical solution for treating burns in field conditions.
In addition, in the private sector, we signed a collaboration agreement with Vericel (Nasdaq: VCEL) for North America. Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets to market and sell NexoBrid to the 140 burn centers across the U.S.
$216M
contracts value
$50M
additional procurement
$125M
Sales milestones
140
Burn Centers
Global Outreach
We strongly believe in empowering our distributors. We recognize the value they bring to our mission and the critical role they play in delivering NexoBrid to burn patients worldwide.
We employ a comprehensive approach to the global commercialization of NexoBrid, utilizing multiple sales channels. Our strategy involves leveraging various avenues to reach our target markets effectively. This includes utilizing our dedicated European direct sales force, as well as engaging sales representatives and partnering with local distributors across the European Union and Asia. By leveraging these diverse sales channels, we ensure widespread availability and accessibility of NexoBrid to burn patients in these regions.
44
COUNTRIES
Holy Stone Healthcare Co., Ltd.
The Republic of China (Taiwan)
- Direct distribution
- Sales representative
- Distributors
Distributors
Our Partners
Join Us
Become a Distributor
We are deeply committed to bringing innovative and life-changing therapies to patients worldwide. Our dedication to improving healthcare outcomes drives us to continuously seek new collaborations and partnerships. By joining forces with like-minded organizations and individuals, we can leverage collective expertise, resources, and networks to accelerate the development, accessibility, and adoption of groundbreaking therapies. We are excited about the future opportunities for collaboration and the positive impact we can make together in transforming patients' lives globally.